[go: up one dir, main page]

BR9810944A - Controle de sìndrome de intestino acìdico - Google Patents

Controle de sìndrome de intestino acìdico

Info

Publication number
BR9810944A
BR9810944A BR9810944-8A BR9810944A BR9810944A BR 9810944 A BR9810944 A BR 9810944A BR 9810944 A BR9810944 A BR 9810944A BR 9810944 A BR9810944 A BR 9810944A
Authority
BR
Brazil
Prior art keywords
acidic
bowel syndrome
animal
human
control
Prior art date
Application number
BR9810944-8A
Other languages
English (en)
Inventor
James Baber Rowe
Original Assignee
Univ New England
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New England filed Critical Univ New England
Publication of BR9810944A publication Critical patent/BR9810944A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"CONTROLE DE SìNDROME DE INTESTINO ACìDICO"<D>. De acordo com a presente invenção é provido um método para o tratamento ou profilaxia da síndrome do intestino acídico, resultando do acúmulo de ácido e produção de endotoxina no trato gastrointestinal de um humano ou um animal, o referido acúmulo resultando da fermentação de carboidrato no trato gastrointestinal do referido humano ou animal, onde o referido método compreende administrar ao referido humano ou animal uma quantidade eficaz de um agente ativo capaz de prevenir ou controlar o acúmulo de ácido e endotoxina no trato gastrointestinal.
BR9810944-8A 1997-06-27 1998-06-26 Controle de sìndrome de intestino acìdico BR9810944A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7582A AUPO758297A0 (en) 1997-06-27 1997-06-27 Control of acidic gut syndrome
PCT/AU1998/000495 WO1999000136A1 (en) 1997-06-27 1998-06-26 Control of acidic gut syndrome

Publications (1)

Publication Number Publication Date
BR9810944A true BR9810944A (pt) 2000-09-26

Family

ID=3801872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810944-8A BR9810944A (pt) 1997-06-27 1998-06-26 Controle de sìndrome de intestino acìdico

Country Status (8)

Country Link
US (2) US6303572B1 (pt)
EP (1) EP1017402A4 (pt)
JP (1) JP2002511865A (pt)
AU (1) AUPO758297A0 (pt)
BR (1) BR9810944A (pt)
CA (1) CA2294904A1 (pt)
NZ (1) NZ502445A (pt)
WO (1) WO1999000136A1 (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
NZ517706A (en) * 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
CA2417764C (en) * 2000-08-08 2009-05-05 Katsuo Kataoka Highly absorbable solid preparations containing sitafloxacin and tartaric acid
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
WO2002080947A1 (fr) * 2001-04-06 2002-10-17 Kyodoken Institute For Animal Science Research & Development Compositions contenant une bacterie pouvant convertir de l'acide lactique en acide butyrique, et methode utilisant ces compositions pour prevenir ou traiter l'hyperlactacidemie dans le systeme digestif ou le cancer du colon
DK1424067T3 (da) * 2001-08-08 2010-08-30 Dominguez Maria Antonia Garcia-Olmedo Injicerbart skum og hidtil ukendte farmaceutiske applikationer deraf
WO2003084481A2 (en) * 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
GB0209262D0 (en) * 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
US7740838B2 (en) * 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
ES2518316T3 (es) * 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
US7252836B2 (en) 2003-01-13 2007-08-07 Penwest, Ltd. Food and feed compositions including resistant starch
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
NO319624B1 (no) 2003-09-15 2005-09-05 Trouw Internat Bv Fiskefôr for laksefisk i ferskvann og anvendelse av slikt fôr.
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005041657A1 (en) 2003-10-20 2005-05-12 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins
DE10350409A1 (de) * 2003-10-28 2005-05-25 Bayer Healthcare Ag Behandlung genetisch bedingter Krankheiten
US20050220846A1 (en) * 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
SI1828167T1 (sl) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060018843A1 (en) * 2004-07-24 2006-01-26 Fine Kenneth D Halitosis, gingivitis, and periodontitis treatment and preventative composition
US7611732B2 (en) * 2004-07-26 2009-11-03 Michael Bentley Nutritional supplement for osteoarthritis
US20090038023A1 (en) * 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
JP5343212B2 (ja) 2005-03-15 2013-11-13 ヴェレニウム コーポレイション セルラーゼ、それらをコードする核酸、並びにそれらを作製及び使用する方法
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007068055A1 (en) * 2005-12-15 2007-06-21 Hancroft Pty Ltd A method for preventing reduced feed intake in animals and treatment of disease conditions
NZ595498A (en) 2006-02-10 2013-05-31 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
CN101443446B (zh) 2006-03-07 2013-08-21 维莱尼姆公司 醛缩酶、编码它们的核酸及制备和使用它们的方法
EP2316962B1 (en) 2006-03-07 2014-07-09 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2029739A4 (en) * 2006-06-02 2009-11-25 Verenium Corp LYASE ENZYMES, NUCLEIC ACIDS FOR THEIR CODING AND METHOD FOR THEIR PREPARATION AND USE
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
DK2069490T4 (en) 2006-12-21 2018-04-23 Syngenta Participations Ag Amylases and Glucoamylases, Nucleic Acids Encoding Them, and Methods of Preparation and Use thereof
BRPI0807132A2 (pt) 2007-01-30 2018-12-04 Syngenta Participations Ag enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
EP2167069B1 (en) * 2007-05-23 2011-10-26 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US20120058157A1 (en) * 2007-05-23 2012-03-08 Amcol International Corporation Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis
EP2625268B1 (en) 2010-10-06 2015-12-30 BP Corporation North America Inc. Variant cbh i polypeptides
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DE102012207471A1 (de) * 2012-05-04 2013-11-07 Fim Biotech Gmbh Mineralische Verbindung und deren Modifikationen zur Anwendung bei chronisch-entzündlichen Darmerkrankungen
IN2012DE01792A (pt) 2012-06-11 2015-10-16 Council Scient Ind Res
RS58898B1 (sr) 2012-06-19 2019-08-30 Debiopharm Int Sa Prolek derivati (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
ITBS20120137A1 (it) * 2012-09-06 2014-03-07 Ecobase Gmbh Uso di una zeolite micronizzata
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN111671766B (zh) 2013-06-05 2024-03-08 特里赛达公司 用于口服施用的结合质子的聚合物
US20160220602A1 (en) * 2013-06-26 2016-08-04 Tasly Pharmaceutical Group Co., Ltd. Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease
US10383921B2 (en) 2013-08-13 2019-08-20 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
EP2870967A1 (de) * 2013-11-08 2015-05-13 Glock Health GmbH Behandlung entzündlicher Darmerkrankungen mit Klinoptilolith
PL3110437T3 (pl) 2014-02-12 2018-04-30 Omnigen Research, Llc Kompozycja i sposób wspomagania obniżania poziomu stresu cieplnego u zwierząt
MX377154B (es) 2014-12-10 2025-03-07 Tricida Inc Polimeros de union a protones para administracion oral.
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
HUE037476T2 (hu) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polipeptid és immunmodulálás
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EA038405B1 (ru) 2015-06-15 2021-08-24 4Д Фарма Рисёрч Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ШТАММЫ БАКТЕРИИ Bifidobacterium breve, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПАТОЛОГИЧЕСКОГО СОСТОЯНИЯ, ОПОСРЕДОВАННОГО IL-17 ИЛИ Th17
RS59308B1 (sr) 2015-06-15 2019-10-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
TW202223083A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CA2998157A1 (en) * 2015-09-15 2017-03-23 Nutriquest, Llc Antimicrobial clay compositions and methods of using
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3209310T (pt) 2015-11-20 2018-04-20 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3419628T (pt) 2016-02-26 2021-01-05 Debiopharm Int Sa Medicamento para o tratamento de infeções do pé diabético
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
MX2018013476A (es) 2016-05-06 2019-03-28 Tricida Inc Composiciones para tratar trastornos acido-base.
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MA48939B1 (fr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
TW201919670A (zh) 2017-06-14 2019-06-01 英商4D製藥研究有限公司 包含細菌品系之組成物
DK3600363T3 (da) 2017-06-14 2021-01-25 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
CA3066557A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
WO2019023320A1 (en) * 2017-07-25 2019-01-31 Arizona Board Of Regents On Behalf Of Arizona State University FAST ANTIBIOTIC SENSITIVITY TESTING BY MONITORING THE SUBMICRON SCALE MOVEMENT OF SIMPLE BACTERIAL CELLS
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
CA3129508A1 (en) 2019-02-14 2020-08-20 Debiopharm International S.A. Solid formulations of afabicin with histidine
WO2020243704A1 (en) 2019-05-31 2020-12-03 Nutriquest, Llc Therapeutic clay compositions and methods of using
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
CN111895706B (zh) * 2020-07-14 2025-05-09 郑州金域临床检验中心有限公司 一种组织蜡块便携制冷、转移、提示控制系统及其装置
CN113769064A (zh) * 2021-09-28 2021-12-10 上海交通大学医学院附属第九人民医院 硫链丝菌素在制备牙周炎治疗药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335704B1 (en) 1988-03-30 1993-09-29 James Baber Rowe Treatment of equine livestock
AU698600B2 (en) 1994-12-29 1998-11-05 James Baber Rowe Prevention of adverse behaviour, diarrhoea, skin disorders and infections of the hindgut associated with acidic conditions in humans and animals
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome

Also Published As

Publication number Publication date
EP1017402A1 (en) 2000-07-12
US6468964B1 (en) 2002-10-22
US6303572B1 (en) 2001-10-16
JP2002511865A (ja) 2002-04-16
CA2294904A1 (en) 1999-01-07
AUPO758297A0 (en) 1997-07-24
NZ502445A (en) 2003-03-28
WO1999000136A1 (en) 1999-01-07
EP1017402A4 (en) 2001-05-30

Similar Documents

Publication Publication Date Title
BR9810944A (pt) Controle de sìndrome de intestino acìdico
SE9800550D0 (sv) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BRPI9509286B8 (pt) microcápsulas medicamentosas e/ou nutricionais para administração per si.
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
BRPI0016231B8 (pt) composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo
BR9812965A (pt) Métodos para tratamento de estados hipercoaguláveis ou deficiência de proteìna c adquirida
BR0315868A (pt) Método para tratar ou melhorar infecção pulmonar em um paciente portador de fibrose cìstica; e método para tratar ou melhorar infecção pulmonar em um animal
WO2001085256A3 (en) Critical illness neuropathy
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR0008323A (pt) Derivado de gabapentina para a prevenção e o tratamento de dor visceral
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BR9809951A (pt) Método para tratamento da obesidade
WO2003000242A3 (en) Method for the treatment of lymphedema using guaifenesin
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
BG102556A (en) Orally applied pharmaceutical composition with modified release containing 5-asa, and a method for the treatment of intestinal diseases
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR9811319A (pt) Método para proteger um animal contra umadoença crÈnica
EP0699444A3 (en) Composition for the treatment of intestinal wounds or ulcers containing proteins, carbohydrates and fat
PT1331940E (pt) Utilizacao da pentraxina longa ptx3 para o tratamento de doencas provocadas por uma activacao alterada do factor de crescimento fgf-2
ES2104223T3 (es) 2-((2-(n-isobutil-n-metil)amino)-bencilsulfinil)bencimidazol como agente antimicrobiano contra helicobacter pylori.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/12 (2006.01)